NCT06857565View on ClinicalTrials.gov

Study to Evaluate the Efficacy of Lactobacillus Crispatus M247 in the Prevention and Treatment of Recurrent Urinary Tract Infections

NACompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Recurrent Urinary Tract Infection
Interventions
DIETARY_SUPPLEMENT

Lactobacillus crispatus M247

CRISPACT® (Lactobacillus crispatus M247), Pharmextracta, S.p.A

DIETARY_SUPPLEMENT

iNatal-duo® (containing Bifidobacterium animalis subsp. lactis BB-12 and Enterococcus faecium L3)

iNatal-duo®, PharmExtracta S.p.A

Trial Locations (1)

Unknown

Medicine & Technological Innovation Dept. University of Insubria, Varese

All Listed Sponsors
collaborator

Università degli Studi dell'Insubria

OTHER

lead

Liaquat University of Medical & Health Sciences

OTHER

NCT06857565 - Study to Evaluate the Efficacy of Lactobacillus Crispatus M247 in the Prevention and Treatment of Recurrent Urinary Tract Infections | Biotech Hunter | Biotech Hunter